Anita Medepalli
Research Subjects
Research Interests
Anita Medepalli has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ebele M. Umeukeje
Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee
1 shared publication Henry Liberman
Department of Interventional Cardiology, Northside Hospital Cardiovascular Institute, Northside Hospital, Atlanta, GA, USA
1 shared publication- Lalitha C. Medepalli
Cardiology/Cardiooncology, Northside Hospital Atlanta/Northside Hospital Cardiovascular Institute, Atlanta, USA
1 shared publication Tariq S.Mahmood
Department of Oncology, Atlanta Cancer care, affiliated with Northside Hospital Cancer Institute, Atlanta, GA, USA
1 shared publication- Thomas W. Bagwell
Mercer University School of Medicine, Macon, GA, USA
1 shared publication Yoonhee Kim
Family Medicine, Mercer University School of Medicine, Macon, Georgia, USA
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Empowering Change Through Motivational Interviewing
Was not provided for this article.
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Open AccessEmpowering Change Through Motivational Interviewing
Was not provided for this article.
- 19 May 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (5) , e270303
Rectal-cancer mimic of recurrent high-grade prostate adenocarcinoma
High-grade prostate cancer is usually monitored with prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography-CT (PET/CT). We describe an older man with a history of Gleason 9 prostate adenocarcinoma treated with androgen deprivation therapy, external beam radiotherapy and brachytherapy who later developed haematuria and functional decline. Despite a large invasive pelvic mass, his PSA remained undetectable, and PSMA PET/CT was negative, initially suggesting an alternative diagnosis such as rectal carcinoma. Colonoscopic biopsy was non-diagnostic, but prostate biopsy confirmed recurrent Gleason 9 adenocarcinoma. The patient deteriorated rapidly and died within 3 months. This case underscores the need for histological confirmation when PSA, PSMA PET/CT, and the clinical picture are discordant, even in previously well-controlled disease.
- 19 May 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (5) , e270303
Rectal-cancer mimic of recurrent high-grade prostate adenocarcinoma
High-grade prostate cancer is usually monitored with prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography-CT (PET/CT). We describe an older man with a history of Gleason 9 prostate adenocarcinoma treated with androgen deprivation therapy, external beam radiotherapy and brachytherapy who later developed haematuria and functional decline. Despite a large invasive pelvic mass, his PSA remained undetectable, and PSMA PET/CT was negative, initially suggesting an alternative diagnosis such as rectal carcinoma. Colonoscopic biopsy was non-diagnostic, but prostate biopsy confirmed recurrent Gleason 9 adenocarcinoma. The patient deteriorated rapidly and died within 3 months. This case underscores the need for histological confirmation when PSA, PSMA PET/CT, and the clinical picture are discordant, even in previously well-controlled disease.
- Open Access
- 15 August 2022
- Published by Springer Nature in Research Square
Diagnosis and management of a patient with 5 FU-induced ST elevation and nonsustained VT as a late presentation of cardiotoxicity and successful rechallenge of 5-FU
5-FU is an antimetabolite drug that is used to treat cancer. It is usually administered to decelerate and prohibit cancer cell proliferation. It acts by inhibiting the enzyme thymidylate synthase by blocking the thymidine formation required for DNA synthesis [1]. The most common clinical manifestation of 5-FU cardiotoxicity is chest pain related to coronary vasospasm [2]. An increase in endothelin-1, a vasoconstrictor, and a decrease in prostacyclin, a vasodilator, is thought to be the cause of endothelial dysfunction, which typically results in coronary vasospasm [3]. Cardiotoxicity induced by 5-FU carries a high risk of morbidity and mortality if it is left untreated [3]. Patients experiencing cardiotoxicity induced by 5-FU present with signs and symptoms of acute coronary syndromes with elevated cardiac biomarkers (troponin), and their ECGs often reveal ST segment differences. There can be two distinct clinical presentations, early or late presentation of cardiotoxicity. Usually, with early toxicity, troponin elevation may be evident. However, in late presentation of cardiotoxicity symptoms, troponin elevation and/or ECG changes may be undetectable. Our case has a unique presentation of 5-FU toxicity in a patient developing ST elevation and nonsustained ventricular tachycardia as a late presentation of cardiotoxicity. Despite the malignant presentation of this vasospasm with continuous infusion 5-FU administration (modified FOLFOX6), our patient was successfully treated and rechallenged with complete bolus 5-FU (FLOX) neoadjuvant chemotherapy. Chakrabarti, S. et al performed a retrospective review of approximately ten patients to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had 5-FU-induced coronary vasospasm. Out of the 10 patients, 8 patients had chest pain as the presenting complaint within 48 hours after beginning the 5-FU infusion. In 9 out of the 10 patients, coronary vasospasm occurred during the first cycle of therapy. All of the patients made a full recovery after the discontinuation of infusion of 5-FU or capecitabine. Subsequently, all patients received FLOX from 7 days to 18 months after the event, with 7 patients treated within 4 weeks of the event. FLOX did not cause any cardiovascular adverse events in any of the 10 patients [4]. Because our patient manifested malignant ST elevation and ventricular tachycardia during the late presentation coronary spasm with 5-FU, the cardio-oncology multidisciplinary team administered a vasodilator pre- and posttreatment regimen. This regimen was described previously in the literature for late presentation of 5-FU cardiotoxicity [5].
- 15 August 2022
- Published by Springer Nature in Research Square
Open AccessDiagnosis and management of a patient with 5 FU-induced ST elevation and nonsustained VT as a late presentation of cardiotoxicity and successful rechallenge of 5-FU
5-FU is an antimetabolite drug that is used to treat cancer. It is usually administered to decelerate and prohibit cancer cell proliferation. It acts by inhibiting the enzyme thymidylate synthase by blocking the thymidine formation required for DNA synthesis [1]. The most common clinical manifestation of 5-FU cardiotoxicity is chest pain related to coronary vasospasm [2]. An increase in endothelin-1, a vasoconstrictor, and a decrease in prostacyclin, a vasodilator, is thought to be the cause of endothelial dysfunction, which typically results in coronary vasospasm [3]. Cardiotoxicity induced by 5-FU carries a high risk of morbidity and mortality if it is left untreated [3]. Patients experiencing cardiotoxicity induced by 5-FU present with signs and symptoms of acute coronary syndromes with elevated cardiac biomarkers (troponin), and their ECGs often reveal ST segment differences. There can be two distinct clinical presentations, early or late presentation of cardiotoxicity. Usually, with early toxicity, troponin elevation may be evident. However, in late presentation of cardiotoxicity symptoms, troponin elevation and/or ECG changes may be undetectable. Our case has a unique presentation of 5-FU toxicity in a patient developing ST elevation and nonsustained ventricular tachycardia as a late presentation of cardiotoxicity. Despite the malignant presentation of this vasospasm with continuous infusion 5-FU administration (modified FOLFOX6), our patient was successfully treated and rechallenged with complete bolus 5-FU (FLOX) neoadjuvant chemotherapy. Chakrabarti, S. et al performed a retrospective review of approximately ten patients to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had 5-FU-induced coronary vasospasm. Out of the 10 patients, 8 patients had chest pain as the presenting complaint within 48 hours after beginning the 5-FU infusion. In 9 out of the 10 patients, coronary vasospasm occurred during the first cycle of therapy. All of the patients made a full recovery after the discontinuation of infusion of 5-FU or capecitabine. Subsequently, all patients received FLOX from 7 days to 18 months after the event, with 7 patients treated within 4 weeks of the event. FLOX did not cause any cardiovascular adverse events in any of the 10 patients [4]. Because our patient manifested malignant ST elevation and ventricular tachycardia during the late presentation coronary spasm with 5-FU, the cardio-oncology multidisciplinary team administered a vasodilator pre- and posttreatment regimen. This regimen was described previously in the literature for late presentation of 5-FU cardiotoxicity [5].